The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000828325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
19/06/2026
Date registered
Help: Date registered
9/07/2026
Date last updated
Help: Date last updated
9/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
9/07/2026
Type of registration
Help: Type of registration
Retrospectively registered

Titles & IDs
Public title
Investigating the impact of providing personalised biological and digital markers of dementia risk via a co-designed, online, interactive, dashboard in Tasmanians over 50 years of age.
Scientific title
Investigating the impact of providing personalised biological and digital markers of dementia risk on modifiable behavioural and lifestyle risk factors via a co-designed, online, interactive, dashboard in Tasmanians over 50 years of age.
Additional trial identifiers [1] 317637 0
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Dementia 342411 0
Condition category
Condition code
Neurological 338546 338546 0 0
Dementias
Neurological 338547 338547 0 0
Alzheimer's disease

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants for INSIGHT co-design dashboard consultation were recruited from a diverse network, ensuring the development process reflected a broad range of perspectives, experiences, and backgrounds. This included individuals from the Wicking Dementia Research & Education Centre, Menzies Institute of Medical Research and a broad group of academics, researchers, general practitioners, geriatricians, neuropsychologists, social workers, psychologists, managerial and nursing staff from the ISLAND Clinic; Tasmania’s one-stop interdisciplinary cognitive clinic. People with lived experience of dementia, their caregivers, indigenous representatives, members of the ISLAND Community Advisory Group and spokespeople from Dementia Australia, the national peak body for dementia in Australia, were all asked to contribute to co-design process. Two, 120-minute workshops were delivered face-to-face at the University of Tasmania’s Medical Science Precinct in Hobart, and two 90-minute workshops were conducted via Zoom to ensure geographical diversity of participants with intra- and interstate participation. A total of 40 participants contributed their expertise and lived experience, totaling seven hours of participation over four weeks. Participants were financially reimbursed for their time and travel expenses. During the iterative co-design process, participants focused on the psychological, behavioral and ethical implications of INSIGHT, ensuring the co-creation of a dashboard that was user-friendly, secure, safe, sensitive, evidence-based, intuitive, ergonomic, and designed to meet the needs of a diverse audience.

The intervention provided to ‘Intervention’ participants as part of INSIGHT will be personalised biological and digital markers of dementia risk. This will be in the form of individual p-tau measurements (in pg/mL), apolipoprotein epsilon-E (APOE) e4 profiles (either e2/e2, e2/e3, e2/e4, e3/e3, e3/e4 or e4/e4) and cognitive results collected via the Cambridge Neuropsychological Test Automated Battery (CANTAB). These results will be presented in an interactive dashboard designed in Aim 1 via an extensive co-design consultation phase. This will be presented alongside further information on “What does this mean?”, where a lay-person summary will be provided explaining the meaning of results. Participants will access the dashboard via their own ISLAND Home Portal, an online interface with secure log-in. There will be further peer-reviewed academic references provided to participants for them to delve further should they wish to do so. The intervention will be available for 3-months, and will be downloadable via PDF should the participant wish to keep the information for their records or pass on to their GP or other health-care professional.
Intervention code [1] 334464 0
Lifestyle
Intervention code [2] 334593 0
Prevention
Description of the comparator or control
Control participants will receive access to no dashboard. Control are reference comparator.
Control group
Active

Outcomes
Primary outcome [1] 345826 0
Modifiable risk factors for dementia
Timepoint [1] 345826 0
Baseline and 3-month follow-up post-intervention
Secondary outcome [1] 463419 0
Psychological wellbeing
Timepoint [1] 463419 0
Baseline and 3-month follow-up post-intervention
Secondary outcome [2] 463420 0
Quality of Life
Timepoint [2] 463420 0
Baseline and 3-month follow-up post-intervention

Eligibility
Key inclusion criteria
INSIGHT forms a sub-study as part of ISLAND (Island Study Linking Ageing and Neurodegenerative Disease), which recruits Tasmanian residents over 50. ISLAND participants who provided a blood sample in 2021 (approximately n=1500) will be eligible to take part in INSIGHTt. These participants were genotyped for apolipoprotein epsilon e4 (APOE4) and a proportion of these (n=750) have undergone analysis for plasma p-tau 181. Only participants who submitted an EOI to have their results communicated to them will be invited to take part in the study.
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria
Participants without biological or digital data needed for the current study (APOE4, p-tau measurement, CANTAB results)

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random sequence
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
TAS

Funding & Sponsors
Funding source category [1] 322176 0
Charities/Societies/Foundations
Name [1] 322176 0
Dementia Australia Research Foundation
Country [1] 322176 0
Australia
Primary sponsor type
University
Name
University of Tasmania
Address
Country
Australia
Secondary sponsor category [1] 325079 0
None
Name [1] 325079 0
Address [1] 325079 0
Country [1] 325079 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320708 0
University of Tasmania Human Research Ethics Committee
Ethics committee address [1] 320708 0
Ethics committee country [1] 320708 0
Australia
Date submitted for ethics approval [1] 320708 0
13/06/2025
Approval date [1] 320708 0
18/09/2025
Ethics approval number [1] 320708 0
H31907

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 151358 0
Dr Eddy Roccati
Address 151358 0
Room 421C, Medical Science Precinct, University of Tasmania, 17 Liverpool St, Hobart, Tasmania, Australia, 7000
Country 151358 0
Australia
Phone 151358 0
+61 03 6226 4228
Fax 151358 0
Email 151358 0
Contact person for public queries
Name 151359 0
Eddy Roccati
Address 151359 0
Room 421C, Medical Science Precinct, University of Tasmania, 17 Liverpool St, Hobart, Tasmania, Australia, 7000
Country 151359 0
Australia
Phone 151359 0
+61 03 6226 4228
Fax 151359 0
Email 151359 0
Contact person for scientific queries
Name 151360 0
Eddy Roccati
Address 151360 0
Room 421C, Medical Science Precinct, University of Tasmania, 17 Liverpool St, Hobart, Tasmania, Australia, 7000
Country 151360 0
Australia
Phone 151360 0
+61 03 6226 4228
Fax 151360 0
Email 151360 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Participant identifiable information including genetics, biological risk indicators and cognitive markers.



What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Study protocol    Roccati_INSIGHT_Protocol_2026_06_18.docx
Ethical approval    Letter (4).pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.